398 related articles for article (PubMed ID: 34269372)
1. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
2. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
3. Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC.
Li J; Yan T; Wu X; Ke X; Li X; Zhu Y; Yang J; Li Z
BMC Cancer; 2021 Nov; 21(1):1205. PubMed ID: 34772357
[TBL] [Abstract][Full Text] [Related]
4. Profiles of immune cell infiltration in head and neck squamous carcinoma.
Liang B; Tao Y; Wang T
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
[TBL] [Abstract][Full Text] [Related]
5. The Expression and Survival Significance of FOXD1 in Lung Squamous Cell Carcinoma: A Meta-Analysis, Immunohistochemistry Validation, and Bioinformatics Analysis.
Xie F; Li Y; Liang B
Biomed Res Int; 2022; 2022():7798654. PubMed ID: 35607308
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
7. FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer.
Mu L; Zhang J; Wu Z; Huang J; Cui Y
J Healthc Eng; 2022; 2022():6108241. PubMed ID: 35126932
[TBL] [Abstract][Full Text] [Related]
8. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
9. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
10. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
[TBL] [Abstract][Full Text] [Related]
12. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
[No Abstract] [Full Text] [Related]
13. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
14. SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma.
Yang ML; Zhang JH; Li S; Zhu R; Wang L
Pathol Oncol Res; 2021; 27():1609967. PubMed ID: 34840533
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
16. CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
Wu Z; Zhu Z; Wu W; Hu S; Cao J; Huang X; Xie Q; Deng C
Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3143-3156. PubMed ID: 38507078
[TBL] [Abstract][Full Text] [Related]
17. FOXD1-AS1 upregulates FOXD1 to promote oral squamous cell carcinoma progression.
Ma Y; Han J; Luo X
Oral Dis; 2023 Mar; 29(2):604-614. PubMed ID: 34403535
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
[TBL] [Abstract][Full Text] [Related]
20. Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
Chai F; Zhang J; Fu T; Jiang P; Huang Y; Wang L; Yan S; Yan X; Yu L; Xu Z; Wang R; Xu B; Du X; Jiang Y; Zhang J
Channels (Austin); 2023 Dec; 17(1):2208928. PubMed ID: 37134043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
